On January 3, 2022 Immix Biopharma (NASDAQ:IMMX) has jumped ~56.7% in the pre-market on above average volume after the company reported that the FDA granted the Rare Pediatric Disease (RPD) designation for IMX-110, a cancer candidate targeted at children (Press release, Immix Biopharma, JAN 3, 2022, View Source [SID1234598017]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– FDA’s RPD for IMX-110 relates to rhabdomyosarcoma, a potentially fatal form of pediatric cancer in children, and the experimental therapy is currently undergoing a Phase 1b/2a clinical trial.

– In awarding RPD, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger.

– If the drugs with the RPD wins approval from the FDA, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRV can be redeemed to receive priority review for any subsequent marketing application, or it can be sold or transferred.

– The latest regulatory triumph for Immix (IMMX) comes less than a month since its IPO.

On January 3, 2022 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 40th Annual JP Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 PM ET (Press release, Ultragenyx Pharmaceutical, JAN 3, 2022, View Source [SID1234598009]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On January 3, 2022 Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported that it will participate in the following upcoming virtual investor conferences (Press release, Ryvu Therapeutics, JAN 3, 2022, https://www.prnewswire.com/news-releases/ryvu-therapeutics-to-participate-in-the-lifesci-partners-11th-annual-corporate-access-event-and-hc-wainwright-bioconnect-conference-301452631.html [SID1234597996]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual LifeSci Partners Corporate Access Event, taking place January 5-7, 2022; Ryvu Therapeutics will host 1×1 investor meetings during the conference.
Registration: LifeSci Partners Corporate Access Event 2022

H.C. Wainwright Bioconnect Virtual Conference, taking place January 10-13, 2022;
Ryvu’s pre-recorded corporate presentation will be available on-demand on the event platform, starting January 10, 7:00 AM (ET). Ryvu’s Management Board will also host investor meetings during the conference.

On January 3, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference (Press release, Curis, JAN 3, 2022, https://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright-bioconnect-conference-301452433.html [SID1234597995]). The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

On January 3, 2022 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that it will release its financial results for the fourth quarter and full year 2021 before the market opens on Wednesday, February 2, 2022, and will hold a conference call on the same day at 8:30 a.m. EST (Press release, Thermo Fisher Scientific, JAN 3, 2022, View Source [SID1234597992]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 986581. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under "Financial Results." A replay of the call will be available under "Webcasts and Presentations" through Friday, February 11, 2022.